Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Event	15. Subsequent Event As discussed in Note 2, on July 23, 2023, the stockholders of MEI voted against the approval of the Merger and the Merger Agreement terminated on July 23, 2023. Following the termination of the Merger Agreement, on July 24, 2023, our board of directors approved a strategic restructuring to preserve our resources. As a result, we will reduce our overall headcount by 21 positions, representing approximately 78% of our workforce. We expect to incur approximately $2.5 million and $0.9 million in total restructuring charges in research and development expenses and general and administrative expenses, respectively, during the third quarter of 2023. These charges primarily consist of severance payments, employee benefits and related taxes, and write-off of prepaid expenses and other assets for services that are no longer expected to continue. Of the aggregate restructuring costs, we expect approximately $3.4 million to be settled through future cash expenditures. We expect the workforce reduction will be substantially complete by the end of the third quarter of 2023.

INFINITY PHARMACEUTICALS, INC. 10-Q